Testing a combination of two medications for advanced prostate cancer

Plain-English translation of NCT06130995 on ClinicalTrials.gov ↗ · Source last updated March 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This trial is testing a combination of two medications called in men with advanced prostate cancer who are also receiving radiation therapy or surgery. These medications work by blocking hormones that fuel prostate cancer growth. Researchers want to see if giving this medication combination before and after your main treatment (surgery or radiation) helps control the cancer better and keeps it from coming back.

Currently, doctors don't have a clear standard for how long to give hormonal therapy to men with high-risk prostate cancer who are getting surgery or radiation. This trial exists to find out if this specific two-drug combination, given for a longer period, can improve survival and prevent cancer recurrence better than current treatment approaches.

Do you qualify?

You likely qualify if…

you are 18 years of age or older
you have been diagnosed with locally advanced prostate cancer that is considered high-risk (based on PSA levels, tumor grade, or how far the cancer has spread)
you are a candidate for radiation therapy or surgery as your main treatment
you have healthy kidney, liver, and bone marrow function based on blood tests
you are able to swallow pills and are willing to use contraception during treatment and for 3 months after

You likely don't qualify if…

you have had a heart attack, stroke, or serious heart failure within the past 6 months
your prostate cancer has spread to distant parts of your body (stage IV metastatic disease)
you are currently taking other experimental cancer medications
you have an active cancer other than prostate cancer that requires treatment
you have an allergy to either of the study medications or similar drugs

What participation looks like

You would take the two medications by mouth daily for 6 months before your surgery or radiation therapy begins. After your main treatment, you would continue taking the medications for an additional 18 months. Throughout this time, you'll have regular clinic visits for blood tests, check-ups, and monitoring. The entire study participation lasts about 24 months from start to finish, including follow-up visits after treatment ends.

AI-generated summary from trial data · Jul 9, 2026 · Not medical advice

Trial locations(1 site)

United States

Stephenson Cancer Center at OU Health, University of Oklahoma Health Sciences Center (SCC-OUHSC), Oklahoma City, Oklahoma